Progressive multifocal leukoencephalopathy

PURPOSE OF REVIEW Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the human CNS that has gained new importance because of AIDS and newer immunosuppressive therapies. It destroys oligodendrocytes, leading to neurologic deficits associated with demyelination. RECENT FINDINGS PML most commonly occurs in patients who are HIV infected, but increasing numbers of patients are being recognized in the context of immunosuppressive therapies for autoimmune diseases. The precise pathogenesis of infection by JC virus, the etiologic human papovavirus, remains elusive, but much has been learned since the original description of the pathologic entity PML in 1958. Detection and diagnosis of this disorder have become more sophisticated with MRI of the brain and spinal fluid analysis using PCR detection. Immune reconstitution inflammatory syndrome complicates reversal of immunosuppression when PML has established a foothold in the brain. SUMMARY No effective therapy exists, but there is hope for better management of patients by withdrawing exogenous immunosuppression and reconstituting the immune system, with a projection of better long-term survival.

[1]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. , 2009, Archives of dermatology.

[2]  H. Hollander,et al.  JC virus DNA in cerebrospinal fluid of human immunodeficiency virus—infected patients: Predictive value for progressive multifocal leukoencephalopathy , 1995, Annals of neurology.

[3]  U. de Girolami,et al.  Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual , 2003, Neurology.

[4]  E. Major From telomeres to T‐antigens: Many roads … multiple pathways … novel associations in the search for the origins of human gliomas , 2000, Annals of neurology.

[5]  E. Major,et al.  Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV , 1990, Journal of neuroscience research.

[6]  M. Post,et al.  Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. , 1993, Radiology.

[7]  I. Fong,et al.  Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy , 1995, Journal of clinical microbiology.

[8]  B. Roth,et al.  The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells , 2004, Science.

[9]  A. Aksamit Nonradioactive in situ hybridization in progressive multifocal leukoencephalopathy. , 1993, Mayo Clinic proceedings.

[10]  A. Antinori,et al.  Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy , 1999, Neurology.

[11]  E. Altschuler,et al.  Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone , 2007, Bone Marrow Transplantation.

[12]  P. Algra,et al.  Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS , 1991, The Lancet.

[13]  G. Z. Zu Rhein,et al.  Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease , 1965, Science.

[14]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[15]  E. Major,et al.  Progressive multifocal leukoencephalopathy: Investigation of three cases using in situ hybridization with JC virus biotinylated DNA probe , 1985, Annals of neurology.

[16]  D. Dickson,et al.  Leflunomide-associated progressive multifocal leukoencephalopathy. , 2008, Archives of neurology.

[17]  H. Kretzschmar,et al.  Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus‐specific DNA from cerebrospinal fluid , 1994, AIDS.

[18]  E. Richardson Progressive multifocal leukoencephalopathy. , 1961, The New England journal of medicine.

[19]  E. Major,et al.  Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact. , 1997, Intervirology.

[20]  H. Fleury,et al.  Improvement of Progressive Multifocal Leukoencephalopathy After Cidofovir Therapy in a Patient with a Destructive Polyarthritis , 2007, Infection.

[21]  A. d’Arminio Monforte,et al.  Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study , 2001, Journal of NeuroVirology.

[22]  J. Berger Steroids for PML-IRIS , 2009, Neurology.

[23]  A. De Luca,et al.  Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: A new clinical entity? , 2004, Neurology.

[24]  J. Delfraissy,et al.  Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: A monocenter observational study with clinical and JC virus load monitoring , 2011, Journal of NeuroVirology.

[25]  J. Rockstroh,et al.  Progressive Multifocal Leukencephalopathy in Patients on Highly Active Antiretroviral Therapy: Survival and Risk Factors of Death , 2004, Journal of acquired immune deficiency syndromes.

[26]  C. Kufta,et al.  Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. , 1988, The New England journal of medicine.

[27]  E. Major,et al.  Progressive multifocal leukoencephalopathy: JC virus detection by in situ hybridization compared with immunohistochemistry , 1986, Neurology.

[28]  B. Brooks,et al.  Progressive multifocal leukoencephalopathy. , 1984, Neurologic clinics.

[29]  A. Aksamit Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside , 2011, Journal of NeuroVirology.

[30]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[31]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[32]  R. Herndon,et al.  Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. , 1972, The New England journal of medicine.

[33]  W. Knowles,et al.  Detection of JC virus DNA in the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy , 1993, Journal of medical virology.

[34]  J. Hauw,et al.  [Progressive multifocal leukoencephalopathy and multiple gliomas]. , 1974, Revue neurologique.

[35]  C. Marra,et al.  Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis , 2008, AIDS.

[36]  G. D. Dal Pan,et al.  Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. , 1998, Journal of neurovirology.

[37]  I. Koralnik Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? , 2006, Annals of neurology.

[38]  A. Aksamit Progressive multifocal leukoencephalopathy: A review of the pathology and pathogenesis , 1995, Microscopy research and technique.

[39]  E. Mowry,et al.  PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA , 2007, Neurology.

[40]  S. Torp,et al.  Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. , 2007, Clinical neuropathology.

[41]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[42]  S. Houston,et al.  Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  K. Johnson,et al.  Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. , 1973, JAMA.

[44]  D. Reich,et al.  Progression of progressive multifocal leukoencephalopathy despite treatment with β-interferon , 2006, Neurology.

[45]  J. Mallolas,et al.  Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  A. Lazzarin,et al.  Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  W. Atwood,et al.  Infection of Glial Cells by the Human Polyomavirus JC Is Mediated by an N-Linked Glycoprotein Containing Terminal α(2-6)-Linked Sialic Acids , 1998, Journal of Virology.

[48]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[49]  A. Aksamit Review of Progressive Multifocal Leukoencephalopathy and Natalizumab , 2006, The neurologist.

[50]  D. Lanska,et al.  Progressive multifocal leukoencephalopathy in patients with HIV infection. , 1998, Journal of neurovirology.

[51]  L. Calabrese,et al.  Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies , 2008, Annals of the rheumatic diseases.

[52]  L. Mucke,et al.  Prolonged survival and partial recovery in AIDS‐associated progressive multifocal leukoencephalopathy , 1988, Neurology.

[53]  G. Sevlever,et al.  Immune reconstitution inflammatory syndrome associated with PML in AIDS: A treatable disorder , 2006, Neurology.

[54]  U. Dafni,et al.  Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. , 1998, The New England journal of medicine.

[55]  H. Vinters,et al.  Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature , 1993, Journal of Neurology.

[56]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[57]  J. McArthur,et al.  PML-IRIS in patients with HIV infection , 2009, Neurology.

[58]  A. Sandrock,et al.  Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1 , 2011, Annals of neurology.

[59]  R. Price,et al.  Progressive multifocal leukoencephalopathy: A burnt‐out case , 1983, Annals of neurology.

[60]  J. Berger,et al.  Opportunistic infections and other risks with newer multiple sclerosis therapies , 2009, Annals of neurology.

[61]  M. Hallek,et al.  Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine. , 2007, Rheumatology.

[62]  G. Gallia,et al.  Review: JC virus infection of lymphocytes--revisited. , 1997, The Journal of infectious diseases.

[63]  H. Hartung,et al.  Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. , 2007, Archives of neurology.

[64]  T. F. Smith,et al.  Detection of JC virus by polymerase chain reaction in cerebrospinal fluid from two patients with progressive multifocal leukoencephalopathy , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[65]  E. Ringelstein,et al.  Efficacy of camptothecin in progressive multifocal leucoencephalopathy , 1997, The Lancet.

[66]  S. Croul,et al.  Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme , 2000, Annals of neurology.

[67]  D. Clifford,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy. , 2012 .

[68]  E. Major,et al.  JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab , 2010, Annals of neurology.

[69]  E. Mancall,et al.  Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. , 1958, Brain : a journal of neurology.

[70]  F. Mandelli,et al.  Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. , 1992, Acta neurologica Belgica.

[71]  Mary G. George,et al.  Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008 , 2011, Annals of neurology.

[72]  R. Frisque,et al.  Human polyomavirus JC virus genome , 1984, Journal of virology.

[73]  R. D. Pasquier,et al.  Inflammatory reaction in progressive multifocal leukoencephalopathy: Harmful or beneficial? , 2011, Journal of NeuroVirology.

[74]  B. Padgett,et al.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. , 1971, Lancet.

[75]  E. Major,et al.  Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain , 1992, Clinical Microbiology Reviews.

[76]  A. J. Wright,et al.  Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. , 2001, Mayo Clinic proceedings.

[77]  Berger,et al.  Progressive Multifocal Leukoencephalopathy. , 2020, Current treatment options in neurology.

[78]  J. Kepes,et al.  Progressive multifocal leukoencephalopathy with 10‐year survival in a patient with nontropical sprue , 1975, Neurology.

[79]  D. Clifford,et al.  A PILOT STUDY OF CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS , 2002, AIDS.

[80]  T. Ernst,et al.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy , 2003, Journal of NeuroVirology.

[81]  J. Bogousslavsky,et al.  Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[82]  H. Petry,et al.  Cellular and humoral immune response in progressive multifocal leukoencephalopathy , 2001, Annals of neurology.

[83]  A. Schapira,et al.  Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon , 1993, Annals of neurology.

[84]  D. Clifford,et al.  Progressive multifocal leukoencephalopathy in transplant recipients , 2011, Annals of neurology.

[85]  D M Simpson,et al.  HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy , 1999, Neurology.

[86]  P. Calabresi,et al.  Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale , 2005, Neurology.

[87]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[88]  J. McArthur,et al.  The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS , 2011, Journal of NeuroVirology.

[89]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.